Refractory Large favorably

Just fill in the form below, click submit, you will get the price list, and we will contact you within one working day. Please also feel free to contact us via email or phone. (* is required).

  • Tisagenlecleucel Demonstrates High Rates of Durable ...

    2021-7-24 · The CAR T-cell product tisagenlecleucel has been shown to elicit durable responses in adult patients with relapsed/refractory follicular lymphoma with a safety profile that compares favorably with ...

    Get Price
  • Axicabtagene Ciloleucel CAR T-Cell Therapy in

    2017-12-10 · In 101 patients with refractory large B-cell lymphoma, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy (axicabtagene ciloleucel) resulted in an overall response rate of 82%, with a 52% ...

    Get Price
  • Safety of axicabtagene ciloleucel for

    2021-4-12 · Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-cell Therapy in Refractory Large B-cell Lymphoma. N Engl J Med. 2017;377:2531–44.

    Get Price
  • Relapsed/Refractory DLBCL Has Extended Response

    2021-6-14 · Forty percent of patients were refractory to their last treatment in the every-3-week group and 13.3% were refractory in the weekly group. As of data cutoff on January 13, 2021, 36.0% of patients with DLBCL treated every 3 weeks in cohort A had completed ≥6 cycles of treatment, as did 50% treated with weekly naratuximab emtansine in cohort B, and 60% of patients with NHL treated every 3 weeks in …

    Get Price
  • Outcomes in refractory diffuse large B-cell lymphoma ...

    Relapsed/refractory diffuse large B-cell lymphoma is a disease with a poor prognosis (2), with 3-year overall survival of 49% after salvage treatment (3). Recent clinical trial results showed ...

    Get Price
  • EMA Review of Axicabtagene Ciloleucel (Yescarta) for

    On June 28, 2018, the Committee for Advanced Therapies and the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Yescarta for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma, after two or more lines of systemic …

    Get Price
  • Tisagenlecleucel Demonstrates High Rates of Durable ...

    2021-7-23 · Newswise — HACKENSACK, N.J. (DATE TK) — A new study has found that using CAR T-cell therapy as the second line of treatment for diffusing large B-cell lymphoma (DLBCL) that has returned or continued to grow after initial treatment was more effective than the standard second-line regimen of care for improving event-free survival (EFS defined as disease progression, needing to start a new …

    Get Price
  • Autologous Peripheral Blood Stem Cell Transplant for ...

    2004-11-16 · Although there may be a benefit to autologous transplant in relapsed anaplastic large cell lymphomas, relapsed/refractory T-cell NHL had inferior long term overall survival compared to their B-cell counterpart transplanted with the same regimen. Novel approaches should be considered in the treatment of relapsed or refractory T-cell NHL.

    Get Price
  • Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T

    2020-12-31 · For those with relapsed or refractory disease, salvage chemotherapy regimens followed by high-dose chemotherapy and autologous stem-cell transplant (ASCT) is a common strategy, however, only half of those with chemo-responsive disease receive ASCT in China. 3, 4 Once failing second-line therapy, these patients have few therapeutic options beyond additional cycles of salvage …

    Get Price
  • (PDF) Cost Effectiveness of Chimeric Antigen Receptor

    2019-6-3 · palliative care are modeled as poor survival, low quality of life, and high monthly costs. Multiply R/R DLBCL, multiple relapsed or refractory diffuse large

    Get Price
  • Axicabtagene Ciloleucel CAR T-Cell Therapy in

    2017-12-10 · BackgroundIn a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B …

    Get Price
  • Naratuximab Emtansine With Rituximab Leads to

    2021-6-12 · Naratuximab emtansine in combination with rituximab showed deep responses and a duration of response that was not reached in patients with relapsed or refractory diffuse large B-cell lymphoma, according to findings from a phase 2 trial presented during the EHA 2021 Virtual Congress.

    Get Price
  • Phase I/II trial of lenalidomide, methotrexate,

    2021-5-17 · Dear Editor, Lenalidomide has moderate activity in relapsed or refractory diffuse large B cell lymphoma (r/rDLBCL) 1.Based on the COMLA regimen used in the 1970s and 1980s 2, we combined lenalidomide with methotrexate (plus leucovorin), cytarabine, and rituximab (LeMLAR) in a phase I/II trial.Lenalidomide induces apoptosis and cell cycle arrest in the G0/G1 phase 3.

    Get Price
  • Real-world experience of Axicabtagene Ciloleucel and ...

    2021-7-19 · Micro abstract: This retrospective study of 53 patients with relapsed or refractory aggressive B-cell lymphomas who received CD19-directed chimeric antigen T-cell receptor therapies at a large academic institution demonstrated similar overall and complete response rates to those reported in the landmark ZUMA-1 and JULIET trials. Double or triple hit status was the only clinical feature ...

    Get Price
  • How Fear of COVID-19 Can Affect Treatment Choices

    Background: The t (2; 5) chromosomal rearrangement of the ALK gene with nucleophosmin 1 gene (NPM1), resulting in an NPM1-ALK fusion, was first demonstrated in 1994 in anaplastic large cell lymphoma, (ALCL), a T-cell lymphoma responsive to cyclophosphamide, abriblastine, vincristine and prednisone in approximately 80% of cases; refractory cases usually respond favorably to brentuximab …

    Get Price
  • (PDF) Chimeric antigen receptor T‐cell therapy after ...

    Conclusions: In this multicenter study, patients with refractory large B-cell lymphoma who received CAR T-cell therapy with axi-cel had high levels of durable response, with a safety profile that ...

    Get Price
  • Autologous Peripheral Blood Stem Cell Transplant for ...

    2004-11-16 · Although there may be a benefit to autologous transplant in relapsed anaplastic large cell lymphomas, relapsed/refractory T-cell NHL had inferior long term overall survival compared to their B-cell counterpart transplanted with the same regimen. Novel approaches should be considered in the treatment of relapsed or refractory T-cell NHL.

    Get Price
  • Novel drug targets for personalized precision

    2015-12-11 · Diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous lymphoid malignancy and the most common subtype of non-Hodgkin’s lymphoma in adults, with one of the highest mortality rates in most developed areas of the world. More than half of DLBLC patients can be cured with standard R-CHOP regimens, however approximately 30 to 40 % of patients will develop relapsed/refractory …

    Get Price
  • Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T

    2020-12-31 · 1 INTRODUCTION. Non-Hodgkin's lymphoma (NHL) was diagnosed in over a half million persons worldwide in 2018. 1 In China, 68,500 new cases, 37,600 deaths and 237,000 existing cases of NHL were estimated in 2016. 2 Chinese large B-cell lymphoma (LBCL) patients typically receive R-CHOP as frontline therapy. For those with relapsed or refractory disease, salvage chemotherapy regimens …

    Get Price
  • Mesothelin-Targeted CARs: Driving T Cells to Solid

    2016-2-1 · Chimeric antigen receptors (CAR) are synthetic receptors that target T cells to cell-surface antigens and augment T-cell function and persistence. Mesothelin is a cell-surface antigen implicated in tumor invasion, which is highly expressed in mesothelioma and lung, pancreas, breast, ovarian, and other cancers. Its low-level expression in mesothelia, however, commands thoughtful therapeutic ...

    Get Price
  • BCG-Refractory NMIBC Treatment: Present and Future

    BCG-Refractory NMIBC Treatment: Present and Future Angela B. Smith, MD, MS, FACS ... • 12-month OS compares favorably to previous estimates of 20% in a 2L setting1 IC2/3 n = 100 IC0/1 n = 210 All N = 310 MedianOS ... •Large amount of clinical investigation ongoing for

    Get Price
  • Duvelisib Exposure to Enhance Immune Profiles of T

    2021-5-18 · Duvelisib, an oral phosphoinositide 3-kinase (PI3K) inhibitor, may favorably change a patient's T cells to make them more efficient and have a longer duration for manufacturing of CAR-T cells. Condition or disease Intervention/treatment Phase ; Recurrent Diffuse Large B-Cell Lymphoma Refractory Diffuse Large B-Cell Lymphoma: Drug: Duvelisib ...

    Get Price
  • Diagnosis and Management of Refractory

    Diagnosis and Management of Refractory Gastroesophageal Reflux Disease. Amit Patel, MD and Rena Yadlapati, MD. ... prominent regurgitation responds more favorably to antireflux surgery ... and moderately appropriate for patients with a positive RSA for regurgitation and a large hiatal hernia with normal AET. 22 As with any medical treatment or ...

    Get Price
  • Palliative Long-Term Abdominal Drains Versus Large

    2020-12-19 · Nurses also viewed the LTAD favorably, though expressed the need for additional support should this become standard of care. Conclusion. ... Palliative long-term abdominal drains versus large volume paracentesis in refractory ascites due to cirrhosis: a feasibility randomised controlled trial. Aliment Pharmacol Ther, 52 ...

    Get Price
  • Phase I/II trial of lenalidomide, methotrexate,

    2021-5-17 · Dear Editor, Lenalidomide has moderate activity in relapsed or refractory diffuse large B cell lymphoma (r/rDLBCL) 1.Based on the COMLA regimen used in the 1970s and 1980s 2, we combined lenalidomide with methotrexate (plus leucovorin), cytarabine, and rituximab (LeMLAR) in a phase I/II trial.Lenalidomide induces apoptosis and cell cycle arrest in the G0/G1 phase 3.

    Get Price
  • Gemcitabine, dexamethasone, and cisplatin in patients

    2004-9-1 · Patients with recurrent or refractory diffuse large B-cell NHL or variants (REAL classification), measurable disease, and one previous chemotherapy regimen were eligible. Treatment consisted of gemcitabine 1000 mg/m 2 intravenously (i.v.) on Days 1 and 8, dexamethasone 40 mg orally on Days 1–4, and cisplatin 75 mg/m 2 i.v. on Day 1 (GDP ...

    Get Price
  • Refractory hyponatremia - Kidney International

    2015-12-11 · Diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous lymphoid malignancy and the most common subtype of non-Hodgkin’s lymphoma in adults, with one of the highest mortality rates in most developed areas of the world. More than half of DLBLC patients can be cured with standard R-CHOP regimens, however approximately 30 to 40 % of patients will develop relapsed/refractory …

    Get Price
  • Novel drug targets for personalized precision

    2021-1-6 · Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has significantly improved outcomes in the treatment of refractory or relapsed large B-cell lymphoma (LBCL). We evaluated the long-term course of hematologic recovery, immune reconstitution, and infectious complications in 41 patients with LBCL treated with axicabtagene ciloleucel ...

    Get Price
  • Immune reconstitution and infectious complications ...

    2021-3-23 · Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options, depending solely on cytarabine + anthracycline (7 + 3) intensive chemotherapy and hypomethylating agents. Allogeneic stem cell transplantation (Allo-SCT) played an important role to improve the survival of eligible AML patients in the past several decades.

    Get Price
  • BCG-Refractory NMIBC Treatment: Present and Future

    BCG-Refractory NMIBC Treatment: Present and Future Angela B. Smith, MD, MS, FACS ... • 12-month OS compares favorably to previous estimates of 20% in a 2L setting1 IC2/3 n = 100 IC0/1 n = 210 All N = 310 MedianOS ... •Large amount of clinical investigation ongoing for

    Get Price
  • Gemcitabine, dexamethasone, and cisplatin in patients

    2004-9-1 · Patients with recurrent or refractory diffuse large B-cell NHL or variants (REAL classification), measurable disease, and one previous chemotherapy regimen were eligible. Treatment consisted of gemcitabine 1000 mg/m 2 intravenously (i.v.) on Days 1 and 8, dexamethasone 40 mg orally on Days 1–4, and cisplatin 75 mg/m 2 i.v. on Day 1 (GDP ...

    Get Price
  • Lenalidomide in Relapsed or Refractory Diffuse Large

    2016-7-5 · Despite the advent of new treatment strategies, many patients with diffuse large B-cell lymphoma (DLBCL) relapse or die of the disease; hence, novel therapeutic approaches are urgently needed. This study confirms that lenalidomide is a valid and well-tolerated treatment option for relapsed/refractory (R/R) DLBCL.

    Get Price
  • Management of Advanced and Relapsed/Refractory

    Introduction. Extra-nodal natural killer/T-cell lymphoma (ENKL) is a rare lymphoma representing approximately 5–10% of T-cell non-Hodgkin lymphomas diagnosed in the United States each year. 1, 2 ENKL is universally associated with Epstein-Barr virus (EBV) infection, and is more frequent in Asian, Central American and South American populations, where it constitutes 5–15% of all lymphomas ...

    Get Price
  • CAR-T shows ‘significant survival benefit’ vs. standard

    2020-5-28 · “Standardized analyses of ZUMA-1 vs. SCHOLAR-1 indicate a survival benefit in response rates and overall survival with axi-cel compared with salvage regimens in refractory large …

    Get Price
  • Glofitamab, a Novel, Bivalent CD20-Targeting Engaging ...

    2021-6-16 · B-NHL; most were refractory to prior therapy (155; 90.6%) and had received a median of three prior therapies. One hundred and twenty-seven patients (74.3%) had diffuse large B-cell lymphoma, transformed follicular lymphoma, or other aggressive histology, and the remainder had indolent lymphoma subtypes. Five (2.9%)

    Get Price
  • Diagnosis and Management of Refractory

    Abstract: In up to half of patients with symptoms suspected to stem from gastroesophageal reflux disease (GERD), these symptoms persist despite treatment with daily proton pump inhibitor (PPI) therapy. The symptoms may be characterized as typical (eg, heartburn or regurgitation) or atypical (eg, chest pain or cough). These refractory symptoms, which are frequently encountered in clinical ...

    Get Price
  • Emerging Role of T-Cell Therapies in

    2015-9-28 · In most cases of relapsed/refractory mantle cell lymphoma (MCL), patients respond to salvage therapy, though typically responses are partial and/or transient followed by disease progression, even with newer agents (e.g., ibrutinib). In this multicenter, open-label, single-arm, phase II study, patients with relapsed/refractory non-blastoid MCL received bendamustine 90 mg/m2 (days 1 and 2) …

    Get Price
  • Phase II study of bendamustine combined with

    2012-1-24 · Compression properties of a refractory multi-component alloy, Ta20Nb20Hf20Zr20Ti20, were determined in the temperature range of 296–1473 K and strain rate range of 10−1–10−5 s−1. The properties were correlated with the microstructure developed during compression testing. The alloy was produced by vacuum arc melting, and it was hot isostatically pressed (HIPd) and homogenized at 1473 ...

    Get Price
  • BCG-Refractory NMIBC Treatment: Present and Future

    BCG-Refractory NMIBC Treatment: Present and Future Angela B. Smith, MD, MS, FACS ... • 12-month OS compares favorably to previous estimates of 20% in a 2L setting1 IC2/3 n = 100 IC0/1 n = 210 All N = 310 MedianOS ... •Large amount of clinical investigation ongoing for

    Get Price
  • Diagnosis and Management of Refractory

    Diagnosis and Management of Refractory Gastroesophageal Reflux Disease. Amit Patel, MD and Rena Yadlapati, MD. ... prominent regurgitation responds more favorably to antireflux surgery ... and moderately appropriate for patients with a positive RSA for regurgitation and a large hiatal hernia with normal AET. 22 As with any medical treatment or ...

    Get Price
  • Relapsed or Refractory Diffuse Large B-cell Lymphoma ...

    2021-5-27 · DUBLIN--(BUSINESS WIRE)--The 'Relapsed or Refractory Diffuse Large B-cell Lymphoma Market - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028' report has been added to ResearchAndMarkets ...

    Get Price
  • Lenalidomide in Relapsed or Refractory Diffuse Large

    2021-4-30 · INTRODUCTION. Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL). For patients who are refractory to initial treatment or relapse after an initial response, only a small percentage will experience prolonged disease-free survival with salvage chemoimmunotherapy alone [].Evaluation and treatment of relapsed or refractory DLBCL is …

    Get Price
  • Relapsed or refractory diffuse large B cell lymphoma ...

    Refractory hypertension is an extreme phenotype of antihypertensive treatment failure. Participants in the REasons for Geographic And Racial Differences in Stroke (REGARDS) Study, a large (n=30 239), population-based cohort were evaluated to determine the prevalence of refractory hypertension and associated cardiovascular risk factors and comorbidities.

    Get Price
  • Phase II study of bendamustine combined with

    2018-9-11 · Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma Fang Bao, Wei Wan, Ting He, Feifei Qi, Guanghua Liu, Kai Hu, Xin-an Lu, Ping Yang, Fei Dong, Jing Wang

    Get Price